

Submission of Clinical Trial Protocol Notice
for Corneal Endothelial Therapy Cell Therapy, “AE101”

ActualEyes Inc. is pleased to announce the submission of the Phase II clinical trial protocol for "AE101," a cutting-edge therapy for the treatment of bullous keratopathy, to the Pharmaceuticals and Medical Devices Agency (PMDA). After PMDA's 30-day investigation of the clinical trial protocol, we anticipate commencing the clinical trial.

We will promote this clinical trial and make progress toward early effectiveness and safety confirmation to deliver the treatment using cultured human corneal endothelial cells to the patients.

D. Western Therapeutics Institute, Inc. is the co-development company for the product.

Glossary

*1 Bullous keratopathy

Bullous keratopathy is a condition induced by damage to the corneal endothelial cells, leading to visual impairment. Major causes of bullous keratopathy are Fuchs' endothelial corneal dystrophy, cataract surgery, and glaucoma surgery. The current standard treatment is corneal transplantation using deceased donor corneas.

Contact information for inquiries about this announcement

ActualEyes Inc.

Masahiko Kato, Director, Management Department info@actualeyeyes.co.jp